Tu1300 - Comparison of Vonoprazan and High Doses of PPI as the Acid Inhibitor in the Rescue Therapy for Eradication of H. Pylori

2018 ◽  
Vol 154 (6) ◽  
pp. S-927
Author(s):  
Takahisa Furuta ◽  
Mihoko Yamade ◽  
Takahiro Suzuki ◽  
Takahiro Uotani ◽  
Takuma Kagami ◽  
...  
2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Chao-Hung Kuo ◽  
Fu-Chen Kuo ◽  
Huang-Ming Hu ◽  
Chung-Jung Liu ◽  
Sophie S. W. Wang ◽  
...  

This paper reviews the literature about first-line therapies forH. pyloriinfection in recent years. First-line therapies are facing a challenge because of increasing treatment failure due to elevated antibiotics resistance. Several new treatment strategies that recently emerged to overcome antibiotic resistance have been surveyed. Alternative first-line therapies include bismuth-containing quadruple therapy, sequential therapy, concomitant therapy, and hybrid therapy. Levofloxacin-based therapy shows impressive efficacy but might be employed as rescue treatment due to rapidly raising resistance. Rifabutin-based therapy is also regarded as a rescue therapy. Several factors including antibiotics resistance, patient compliance, and CYP 2C19 genotypes could influence the outcome. Clinicians should use antibiotics according to local reports. It is recommended that triple therapy should not be used in areas with high clarithromycin resistance or dual clarithromycin and metronidazole resistance.


Author(s):  
Hyun Soo Kim ◽  
Hyuk Yoon ◽  
Dong Woo Shin ◽  
Dong Jun Oh ◽  
Mingu Kwon ◽  
...  

Background/Aims: The treatment options for Helicobacter pylori (<i>H. pylori</i>) infection are in a state of flux: traditional triple therapies have started to fail, and new treatments are unable to achieve optimal eradication rates. Rifaximin and rifabutin are new antibiotics. The aim of this study was to evaluate the efficacy and safety of adding rifaximin to the standard triple regimen and of a rifabutin-based triple regimen as a rescue therapy for <i>H. pylori</i> eradication.Materials and Methods: We enrolled 27 <i>H. pylori</i>-positive patients who were treated with a proton pump inhibitor, amoxicillin, clarithromycin, and rifaximin for 14 days. <i>H. pylori</i> eradication was assessed by a <sup>13</sup>C-urea breath test performed 4 weeks after therapy completion. The efficacy of the therapy was based on intention-to-treat (ITT) and per-protocol (PP) analysis. We also investigated the resistance rate, compliance, and side effects associated with rifaximin therapy. Minimal inhibitory concentrations and resistance to rifabutin were evaluated using the agar dilution method.Results: Of the 27 patients, 22 completed the treatment protocol with 100% compliance; five patients withdrew. The ITT and PP eradication rates for the rifaximin-containing quadruple therapy were 70.4% (19/27) and 86.3% (19/22), respectively. Adverse events were observed in five of 22 patients (22.7%). The resistance rates to rifaximin and rifabutin were 66.7% (2/3) and 0% (0/3), respectively.Conclusions: The findings of this study show the limitations of rifaximin-based quadruple therapy and suggest the benefits of a rifabutin-based rescue regimen in South Korea.


2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Javier P. Gisbert

Helicobacter pyloriinfection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After 30 years of experience inH. pyloritreatment, however, the ideal regimen to treat this infection has still to be found. Nowadays, apart from having to know well first-line eradication regimens, we must also be prepared to face treatment failures. In designing a treatment strategy, we should not only focus on the results of primary therapy alone but also on the final—overall—eradication rate. The choice of a “rescue” treatment depends on which treatment is used initially. If a first-line clarithromycin-based regimen was used, a second-line metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third-line “rescue” option. Alternatively, it has recently been suggested that levofloxacin-based “rescue” therapy constitutes an encouraging 2nd-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, quadruple regimen may be reserved as a 3rd-line “rescue” option. Even after two consecutive failures, several studies have demonstrated thatH. pylorieradication can finally be achieved in almost all patients if several “rescue” therapies are consecutively given.


2013 ◽  
Vol 144 (5) ◽  
pp. S-334
Author(s):  
Javier P. Gisbert ◽  
Manuel Castro-Fernandez ◽  
Angeles Perez Aisa ◽  
Angel Cosme ◽  
Javier Molina-Infante ◽  
...  
Keyword(s):  

2020 ◽  
Vol 76 (11) ◽  
pp. 1581-1589
Author(s):  
Ming-Tsung Hsieh ◽  
Wei-Lun Chang ◽  
Chung-Tai Wu ◽  
Hsiao-Bai Yang ◽  
Hsin-Yu Kuo ◽  
...  

2000 ◽  
Vol 32 ◽  
pp. A134
Author(s):  
F. Canducci ◽  
V. Ojetti ◽  
E.Sanz Torre ◽  
P. Pola ◽  
G. Gasbarrini ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Seng-Kee Chuah ◽  
Wei-Chen Tai ◽  
Chen-Hsiang Lee ◽  
Chih-Ming Liang ◽  
Tsung-Hui Hu

Fluoroquinolones, especially levofloxacin, are used in the eradication ofHelicobacter pyloriworldwide. Many consensus guidelines recommend that the second-line rescue therapy forH. pylorieradication consists of a proton pump inhibitor, a quinolone, and amoxicillin as an option. Unfortunately, quinolone is well associated with a risk of developing bacterial resistance. In this paper, we review quinolone-containingH. pylorieradication regimens and the challenges that influence the efficacy of eradication. It is generally suggested that the use of levofloxacin should be confined to “rescue” therapy only, in order to avoid a further rapid increase in the resistance ofH. pylorito quinolone. The impact of quinolone-containingH. pylorieradication regimens on public health issues such as tuberculosis treatment must always be taken into account. Exposure to quinolone is relevant to delays in diagnosing tuberculosis and the development of drug resistance. Extending the duration of treatment to 14 days improves eradication rates by >90%. Tailored therapy to detect fluoroquinolone-resistant strains can be done by culture-based and molecular methods to provide better eradication rates. Molecular methods are achieved by using a real-time polymerase chain reaction to detect the presence of agyrAmutation, which is predictive of treatment failure with quinolones-containing triple therapy.


2008 ◽  
Vol 134 (4) ◽  
pp. A-337
Author(s):  
Javier P. Gisbert ◽  
Jose-Luis Gisbert ◽  
Eusebio Marcos ◽  
Isabel Jimenez-Alonso ◽  
Adrian G. McNicholl ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document